MHRA Opens Second AI Airlock Program For Applications

UK Regulatory Agency Receives Additional £1M For Second Cohort

"The AI Airlock program creates a supervised testing ground where novel technologies and challenge areas can be safely investigated," said James Pound, MHRA interim executive director of innovation and compliance.

AI Airlock

Applications for the second cohort of the Medicines and Healthcare products Regulatory Agency’s (MHRA) AI Airlock program opened on June 23, 2025, with an additional £1m ($1.3m) in funding.

The AI Airlock, which was first launched in July 2024, serves as a regulatory testing ground for companies developing AI-powered...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from AI

FDA’s New AI Councils Focus On ‘Responsible’ Adoption And Regulation

 

The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.

Tariffs In Focus: Projections From 4 Medtech Giants (Q1 Vs Q2)

 

Roche Diagnostics, Intuitive Surgical, Abbott and Edwards Lifesciences all acknowledge tariff headwinds, but stress preparedness, resilience and mitigation. Below is look at how management framed the impact in Q1 vs Q2 earnings calls.

Study Finds Public Companies Behind Most Recalled AI Devices

 
• By 

A Johns Hopkins University study found publicly traded companies are responsible for 90% of recalled AI-powered medical devices. The study attributes this link to lower clinical validation, especially among smaller companies, and advocates for increased clinical trials to enhance device safety.

Medtronic Posts Solid First-Quarter, Adds Board Members As Elliott Takes Stake

 
• By 

Medtronic beat first-quarter revenue and EPS estimates, raised guidance, and added two board members and special committees as Elliott takes a stake.

More from Regulation

23andMe Genetic Tests Among 12 New FDA Classifications

 
• By 

A late-August batch of device classifications from the US FDA includes genetic tests from 23andMe, hand-held spinal surgery tools, and several IVDs.

Why EU Innovators Face Growing Barriers With EU Combination Product Regulation

 

Combination products are no longer fringe – they are the “new normal,” consultant Stephen O’Rourke told Medtech Insight. The EU has the expertise to handle the regulatory complexity, but only if connects the dots between silos. That’s the challenge, he said, and the opportunity.

UK MHRA Ready To Evolve Approach To In-House Manufactured Medtech

 
• By 

The UK device regulator wants to align health institution device exemptions with its evolving policy of agile regulation of medtech in the British market. It asks stakeholders to complete a survey by Sept. 15.